小児遺伝性血管性浮腫に対する新規薬剤の使用経験
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Hereditary angioedema (HAE) causes episodic edema involving skin, gastrointestinal tract and larynx, which can be fatal. In recent years, new medications for HAE have received insurance coverage, therefore patients with HAE can choose from various treatment options. We report a pediatric patient with HAE attack, recurrent abdominal pain, treated with novel medications. Before diagnosis, the mean duration of abdominal pain attacks was 66.0 hours. After diagnosis, on-demand therapy with C1-INH concentrate, reduced the mean attack duration to 35.2 hours. Subsequently, self-administered injection of icatibant acetate further reduced the mean attack duration to 6.5 hours. He no longer required unscheduled visits or emergency hospitalizations. Preventive therapy with routine self-administered injection of C1-INH concentrate decreased the median frequency of attack from 2 times per month to once per month. Recurrent abdominal pain should prompt consideration of HAE. Early diagnosis and treatment with preventive and on-demand therapy can improve patient quality of life.
Fields of Study & Subjects
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Complement system in diseases
Hemophilia Treatment and Research
Publication details
- Journal / source
- Institutional Repositories DataBase (IRDB)
- Volume
- 6
- Issue
- 1
- Pages
- 50–55
- Publication date
- 15 March 2026
- Language
- JA